Background: Graves’ orbitopathy (GO) is a potentially sight-threatening and disfiguring, extrathyroidal manifestation of Graves’ disease. It often impairs patients’ quality of life, causing severe social and psychological sequelae. To study the effects of rituximab on graves orbitopathy. Materials & Methods: A total of 10 subjects were enrolled. The Wilcoxon rank sum test for paired samples was employed to compare the Clinical Activity Score (CAS) between baseline and 12 weeks, as well as between baseline and 24 weeks. The p- value less than 0.05 were considered statistically significant. The results were analysed using SPSS software. Results: A total of 10 subjects were enrolled. The average age group was 50-70 years. The number of male subjects was 3(30%). A modest enhancement in the clinical activity score was noted, with a median improvement of 1 point at 24 weeks (p=0.001) conjunctival injection depicted in 50%. Conclusion: Rituximab, known for its favorable tolerance and safety record, showed only modest and incomplete efficacy in treating active moderate-to-severe Graves' ophthalmopathy with a prolonged disease duration.